News stories about Mednax (NYSE:MD) have been trending somewhat positive on Saturday, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mednax earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.7956968359756 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

Mednax (NYSE MD) opened at 42.76 on Friday. The firm has a market cap of $3.94 billion, a price-to-earnings ratio of 13.62 and a beta of 0.40. Mednax has a 12 month low of $41.52 and a 12 month high of $72.13. The firm’s 50-day moving average price is $54.16 and its 200-day moving average price is $61.44.

Mednax (NYSE:MD) last released its quarterly earnings results on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The firm had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. During the same period last year, the firm posted $1.03 EPS. The business’s revenue was up 9.2% on a year-over-year basis. Equities research analysts predict that Mednax will post $3.31 earnings per share for the current year.

MD has been the subject of a number of analyst reports. ValuEngine lowered Mednax from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub upgraded Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. TheStreet lowered Mednax from a “b-” rating to a “c+” rating in a research report on Tuesday, May 16th. Jefferies Group LLC restated a “hold” rating and set a $53.00 price objective (up previously from $50.00) on shares of Mednax in a research report on Thursday, July 6th. Finally, Bank of America Corporation lowered Mednax from a “buy” rating to an “underperform” rating in a research report on Thursday, May 4th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the stock. Mednax currently has a consensus rating of “Hold” and an average price target of $64.00.

WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at

In related news, Director Md Pascal J. Goldschmidt sold 1,969 shares of the firm’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the sale, the director now directly owns 18,072 shares of the company’s stock, valued at approximately $1,040,405.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joseph M. Calabro sold 23,327 shares of the firm’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $55.00, for a total value of $1,282,985.00. Following the sale, the insider now directly owns 296,379 shares of the company’s stock, valued at $16,300,845. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with's FREE daily email newsletter.